Alpine Immune Sciences Inc (DELISTED) (ALPN:DL)
64.97
0.00 (0.00%)
USD |
NASDAQ |
May 20, 16:00
Alpine Immune Sciences Debt to Equity Ratio: 0.00 for March 31, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
March 31, 2024 | 0.00 |
December 31, 2023 | 0.00 |
September 30, 2023 | 0.00 |
June 30, 2023 | 0.00 |
March 31, 2023 | 0.013 |
December 31, 2022 | 0.0188 |
September 30, 2022 | 0.025 |
June 30, 2022 | 0.0573 |
March 31, 2022 | 0.0594 |
December 31, 2021 | 0.0662 |
September 30, 2021 | 0.0744 |
June 30, 2021 | 0.2344 |
March 31, 2021 | 0.1914 |
December 31, 2020 | 0.1629 |
Date | Value |
---|---|
September 30, 2020 | 0.1491 |
June 30, 2020 | 0.6157 |
March 31, 2020 | 0.3987 |
December 31, 2019 | 0.1672 |
September 30, 2019 | 0.1403 |
June 30, 2019 | 0.072 |
March 31, 2019 | 0.0661 |
December 31, 2018 | 0.0943 |
September 30, 2018 | 0.0848 |
June 30, 2018 | 0.077 |
March 31, 2018 | 0.0687 |
December 31, 2017 | 0.0638 |
September 30, 2017 | 0.0601 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Jun 2023
0.6157
Maximum
Jun 2020
0.1249
Average
0.0662
Median
Dec 2021
Debt to Equity Ratio Benchmarks
Vertex Pharmaceuticals Inc | 0.00 |
Eliem Therapeutics Inc | -- |
Regeneron Pharmaceuticals Inc | 0.0703 |
Vera Therapeutics Inc | -- |
Eyenovia Inc | -5.940 |
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 373.65M |
Total Liabilities (Quarterly) | 40.94M |
Shareholders Equity (Quarterly) | 332.70M |
Current Ratio | 9.562 |
Net Debt Paydown Yield | 0.03% |